Skip to main content

Zanubrutinib Side Effects

Medically reviewed by Philip Thornton, DipPharm. Last updated on Sep 19, 2022.

For the Consumer

Applies to zanubrutinib: oral capsules

Side effects include:

Decreased neutrophil count, decreased platelet count, upper respiratory tract infection, decreased WBC count, decreased hemoglobin concentration, rash, bruising, diarrhea, cough.

For Healthcare Professionals

Applies to zanubrutinib: oral capsule


Very common (10% or more): All grades neutropenia (up to 56%), all grades thrombocytopenia (up to 45%) , hemorrhage (up to 32%), all grades anemia (up to 28%) , all grades leukopenia (25%)

Common (1% to 10%): Grade 3 or 4 anemia, Grade 3 or 4 leukopenia, Grade 3 or 4 thrombocytopenia[Ref]


Very common (10% or more): Grade 3 or higher infection (23%)[Ref]


Very common (10% or more): Musculoskeletal pain (e.g., musculoskeletal pain, musculoskeletal discomfort, myalgia, back pain, arthralgia, arthritis) (up to 45%), muscle spasms (10%)[Ref]


Very common (10% or more): Glucose increased (45%), blood uric acid increased (up to 29%), hypokalemia (14%), calcium decreased (27%), hyperkalemia (24%), hypophosphatemia (20%)


Very common (10% or more): Urinary tract infection (up to 15%)[Ref]


Very common (10% or more): ALT increased (28%), bilirubin increased (up to 24%)

Common (1% to 10%): Hepatitis B reactivation[Ref]


Very common (10% or more): Second primary malignancies (13%)[Ref]


Very common (10% or more): Upper respiratory tract infection (up to 44%), pneumonia (up to 22%), cough (up to 21%)[Ref]


Very common (10% or more): Hypertension (12%)

Common (1% to 10%): Atrial fibrillation, atrial flutter[Ref]


Very common (10% or more): Rash (up to 30%), bruising (up to 20%), pruritus (11%)[Ref]


Very common (10% or more): Diarrhea (up to 23%), constipation (up to 16%), nausea (18%)

Uncommon (0.1% to 1%): Gastrointestinal hemorrhage[Ref]


The most common adverse events were neutropenia, thrombocytopenia, upper respiratory tract infection, hemorrhage, rash, anemia and musculoskeletal pain.


Very common (10% or more): Creatinine increased (31%)


Very common (10% or more): Fatigue (up to 15%), peripheral edema (12%), pyrexia (16%)

Common (1% to 10%): Asthenia

Nervous system

Very common (10% or more): Dizziness (11%)

Frequently asked questions


1. "Product Information. Brukinsa (zanubrutinib)." BeiGene USA, Inc (2019):

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.